Remimazolam for intravenous conscious sedation for dental procedures
SAAD & DSTG position statement on clinical use and training
13 September 2022
Remimazolam (Byfavo, Paion) received UK market authorisation for intravenous procedural sedation in 2021 and is now available from suppliers. Webinars and conference speakers are presenting information about the use of Remimazolam in dentistry and SAAD/DSTG are being asked by their members for advice about the training required and the appropriate use for dental sedation.
The Intercollegiate Advisory Committee for Sedation in Dentistry (IACSD) set the current standards for clinical use and training for dentists and doctors providing sedation for dentistry in the UK. The current document pre-dates Remimazolam authorisation and does not cover the use and training required.
SAAD and DSTG have written to IACSD to ask for clarification on the use of Remimazolam specifically if further clinical supervision and logbook cases will be required for clinicians trained in the use of intravenous midazolam. SAAD recommends that members await further clarification before introducing remimazolam into their clinical practice.
-
References:
Byfavo 20 mg powder for solution for injection. Accessed online 06/09/2022 https://www.medicines.org.uk/emc/product/12746/smpc
IACSD (v1.1, 2020) Standards for Conscious Sedation in the Provision of Dental Care. Intercollegiate Advisory Committee for Sedation in Dentistry
